Literature DB >> 18488219

Combined modality immunotherapy and chemotherapy: a new perspective.

Rupal Ramakrishnan1, Scott Antonia, Dmitry I Gabrilovich.   

Abstract

The results of recent clinical trials have demonstrated that cancer vaccines continue to struggle to achieve tangible clinical benefits as monotherapy. Tumor-induced abnormalities in the immune system hamper anti-tumor T cell responses limiting the effectiveness of cancer immunotherapy. Recently, evidence has been mounting to suggest that immunotherapy has the possibility of achieving better success when used in combination with conventional chemotherapy. In clinical trials, immune responses elicited by cancer vaccines appear to augment the effectiveness of subsequent conventional cancer therapies.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18488219     DOI： 10.1007/s00262-008-0531-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN： 0340-7004            Impact factor:   6.968


  23 in total

1.  Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.

Authors:  Martin K Hunn; Evelyn Bauer; Catherine E Wood; Olivier Gasser; Marina Dzhelali; Lindsay R Ancelet; Brigitta Mester; Katrina J Sharples; Michael P Findlay; David A Hamilton; Ian F Hermans
Journal:  J Neurooncol       Date:  2014-10-31       Impact factor: 4.130

2.  Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.

Authors:  Anindya Dasgupta; Jordan E Shields; H Trent Spencer
Journal:  Hum Gene Ther       Date:  2012-04-18       Impact factor: 5.695

Review 3.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

4.  A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.

Authors:  Nancy Lynn Booth; Thomas J Sayers; Alan D Brooks; Cheryl L Thomas; Kristen Jacobsen; Ekaterina I Goncharova; James B McMahon; Curtis J Henrich
Journal:  Cancer Immunol Immunother       Date:  2008-12-17       Impact factor: 6.968

5.  Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice.

Authors:  Romana Mikyskova; Marie Indrova; Ivan Stepanek; Ivan Kanchev; Jana Bieblova; Sarka Vosahlikova; Irena Moserova; Iva Truxova; Jitka Fucikova; Jirina Bartunkova; Radek Spisek; Radislav Sedlacek; Milan Reinis
Journal:  Oncoimmunology       Date:  2017-08-24       Impact factor: 8.110

6.  Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.

Authors:  Zvi G Fridlender; Jing Sun; Sunil Singhal; Veena Kapoor; Guanjun Cheng; Eiji Suzuki; Steven M Albelda
Journal:  Mol Ther       Date:  2010-08-03       Impact factor: 11.454

Review 7.  Therapeutic cancer vaccines in combination with conventional therapy.

Authors:  Mads Hald Andersen; Niels Junker; Eva Ellebaek; Inge Marie Svane; Per Thor Straten
Journal:  J Biomed Biotechnol       Date:  2010-06-29

8.  Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis.

Authors:  Laura Ridolfi; Massimiliano Petrini; Laura Fiammenghi; Anna Maria Granato; Valentina Ancarani; Elena Pancisi; Emanuela Scarpi; Massimo Guidoboni; Giuseppe Migliori; Stefano Sanna; Francesca Tauceri; Giorgio Maria Verdecchia; Angela Riccobon; Linda Valmorri; Ruggero Ridolfi
Journal:  Clin Dev Immunol       Date:  2010-09-27

Review 9.  Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination.

Authors:  Mohamed Labib Salem; David J Cole
Journal:  Cancer Immunol Immunother       Date:  2009-11-18       Impact factor: 6.968

10.  CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network.

Authors:  Alexandre Boissonnas; Fabrice Licata; Lucie Poupel; Sébastien Jacquelin; Luc Fetler; Sophie Krumeich; Clotilde Théry; Sébastian Amigorena; Christophe Combadière
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.